Publications by authors named "Emil Samara"

9Publications

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.

Clin Pharmacol Drug Dev 2019 01 22;8(1):49-59. Epub 2018 May 22.

eResearch Technology, Inc, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.442DOI Listing
January 2019

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis.

J Pain Res 2016 31;9:587-98. Epub 2016 Aug 31.

VA Northern California Health Care System, Mather, CA; Department of Physical Medicine and Rehabilitation, University of California, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JPR.S113138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012851PMC
September 2016

Predicting pediatric age-matched weight and body mass index.

AAPS J 2014 Nov 26;16(6):1372-9. Epub 2014 Aug 26.

Department of Pharmaceutics, College of Pharmacy, University of Florida, 1345 Center Drive, PO Box 100494, Gainesville, Florida, 32610, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-014-9657-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389747PMC
November 2014

Population pharmacokinetics of telavancin in healthy subjects and patients with infections.

Antimicrob Agents Chemother 2012 Apr 17;56(4):2067-73. Epub 2012 Jan 17.

PharmaPolaris International, Inc., Danville, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.05915-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318396PMC
April 2012

Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.

J Clin Pharmacol 2011 Sep 5;51(9):1310-8. Epub 2011 Jan 5.

Rigel Pharmaceuticals, Inc, 1180 Veterans Blvd., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270010381496DOI Listing
September 2011

Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).

J Pharm Sci 2005 Sep;94(9):1949-56

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S002235491631845
Publisher Site
http://dx.doi.org/10.1002/jps.20387DOI Listing
September 2005